Analyst Research Roundup: Varonis Systems, Inc. (VRNS), AtriCure, Inc. (ATRC)

Varonis Systems, Inc. (NASDAQ:VRNS) tinted loss of -4.07% (-2.4 points) to US$56.6. The volume of 0.3 Million shares climbed down over an trading activity of 383.7 Million shares. EPS ratio determined by looking at last 12 month figures is -1.02. Over the same time span, the stock marked US$83.1 as its best level and the lowest price reached was US$47. The corporation has a market cap of US$1.66 Billion.

Varonis Systems, Inc. (NASDAQ:VRNS)’s earnings per share has been growing at a -19.6 percent rate over the past 5 year when average revenue increase was noted as 32.4 percent. The return on equity ratio or ROE stands at -27.2 percent while most common profitability ratio return on investment (ROI) was -14 percent. The company’s institutional ownership is monitored at 94.1 percent. The company’s net profit margin has achieved the current level of -11.5 percent and possesses 89.9 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 6 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 1.86. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

AtriCure, Inc. (NASDAQ:ATRC) is worth US$1.23 Billion and has recently fallen -2.21% to US$32.29. The latest exchange of 0.17 Million shares is below its average trading activity of 263.21 Million shares. The day began at US$32.7 but the price moved to US$32.7 at one point during the trading and finally capitulating to a session high of US$32.7. The stock tapped a 52-week high of US$36.49 while the mean 12-month price target for the shares is US$37.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 6.63, and a price to sales ratio of 6.33. For the past 5 years, the company’s revenue has grown 20%, while the company’s earnings per share has grown -11.3%. With an institutional ownership near 84.8%, it carries an earnings per share ratio of -0.58.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.57.